Literature DB >> 8946426

Intraseptal flumazenil enhances, while diazepam binding inhibitor impairs, performance in a working memory task.

C D Herzog1, R W Stackman, T J Walsh.   

Abstract

GABAA/benzodiazepine receptors in the medial septum modulate the activity of cholinergic neurons that innervate the hippocampus. Injection of benzodiazepine (BDZ) agonists into the medial septum impairs working memory performance and decreases high-affinity choline transport (HAChT) in the hippocampus. In contrast, intraseptal injection of the BDZ antagonist flumazenil increases HAChT and prevents the memory deficits induced by systemic BDZs. The present studies attempted to further characterize the behavioral effects of medial septal injections of flumazenil to an endogenous negative modulator of the GABAA/BDZ receptor complex, diazepam binding inhibitor (DBI). Male Sprague-Dawley rats were cannulated to study the effects of intraseptal injections of these BDZ ligands on spatial working memory, anxiety-related behaviors in the elevated plus maze, and on general locomotor activity. Intraseptal flumazenil (10 nmol/0.5 microliter) produced a delay-dependent enhancement of DNMTS performance after an 8-h, but not a 4-h, delay interval. This promnestic dose of flumazenil had no effect on locomotor activity and did not produce changes in measures of anxiety on the plus maze. Intraseptal injection of DBI had no effect (8 nmol/0.5 microliter) or slightly impaired (4 nmol/0.5 microliter) DNMTS radial maze performance following an 8-h delay, without producing changes in locomotion or plus maze behavior. These data demonstrate that flumazenil has a unique profile of activity in enhancing working memory following intraseptal injection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946426     DOI: 10.1006/nlme.1996.0074

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  7 in total

1.  Hippocampal extracellular signal-regulated kinase signaling has a role in passive avoidance memory retrieval induced by GABAA Receptor modulation in mice.

Authors:  Dong Hyun Kim; Jong Min Kim; Se Jin Park; Seungheon Lee; Chan Young Shin; Jae Hoon Cheong; Jong Hoon Ryu
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

2.  A functional continuum of regulatory anxiety-enhancing peptides. The search for complexes providing the optimal basis for developing inhibitory therapeutic agents.

Authors:  S V Koroleva; I P Ashmarin
Journal:  Neurosci Behav Physiol       Date:  2006-02

3.  Bidirectional effects of benzodiazepine binding site ligands on active avoidance acquisition and retention: differential antagonism by flumazenil and beta-CCt.

Authors:  Miroslav M Savić; Dragan I Obradović; Nenad D Ugresić; James M Cook; P V V S Sarma; Dubravko R Bokonjić
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

4.  GABA(A) receptor blockade enhances memory consolidation by increasing hippocampal BDNF levels.

Authors:  Dong Hyun Kim; Jong Min Kim; Se Jin Park; Mudan Cai; Xiaotong Liu; Seungheon Lee; Chan Young Shin; Jong Hoon Ryu
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 5.  Benzodiazepine dependence and its treatment with low dose flumazenil.

Authors:  Sean David Hood; Amanda Norman; Dana Adelle Hince; Jan Krzysztof Melichar; Gary Kenneth Hulse
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

6.  Optogenetic suppression of the medial septum impairs working memory maintenance.

Authors:  Zachary M Gemzik; Margaret M Donahue; Amy L Griffin
Journal:  Learn Mem       Date:  2021-09-15       Impact factor: 2.699

7.  Hippocampal Transcriptome Profile of Persistent Memory Rescue in a Mouse Model of THRA1 Mutation-Mediated Resistance to Thyroid Hormone.

Authors:  Yiqiao Wang; André Fisahn; Indranil Sinha; Dinh Phong Nguyen; Ulrich Sterzenbach; Francois Lallemend; Saїda Hadjab
Journal:  Sci Rep       Date:  2016-01-08       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.